[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Radioligand Therapy Market, Global Outlook and Forecast 2022-2028

April 2022 | 60 pages | ID: R28FE6FC27EAEN
Market Monitor Global

US$ 3,250.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
This report contains market size and forecasts of Radioligand Therapy in Global, including the following market information:

Global Radioligand Therapy Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Radioligand Therapy market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Actinium 225 (Ac-225) Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Radioligand Therapy include Novartis, Advanced Accelerator Applications, Mercy Radiology, POINT Biopharma Global Inc, Fusion Pharma, Telix Pharmaceuticals Ltd, Lantheus Holdings, Inc, Bayer AG and Curium Pharma and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Radioligand Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Radioligand Therapy Market, by Used Radionuclides, 2017-2022, 2023-2028 ($ millions)

Global Radioligand Therapy Market Segment Percentages, by Used Radionuclides, 2021 (%)
  • Actinium 225 (Ac-225)
  • Lutetium 177 (Lu-177)
  • Gallium 68 (Ga-68)
  • Fluorine 18 (F-18)
  • Other Radionuclides
Global Radioligand Therapy Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Radioligand Therapy Market Segment Percentages, by Application, 2021 (%)
  • Neuroendocrine Neoplasms
  • Prostate Cancer
Global Radioligand Therapy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Radioligand Therapy Market Segment Percentages, By Region and Country, 2021 (%)
  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Russia
    • Nordic Countries
    • Benelux
    • Rest of Europe
  • Asia
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Rest of Asia
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East & Africa
    • Turkey
    • Israel
    • Saudi Arabia
    • UAE
    • Rest of Middle East & Africa
Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Radioligand Therapy revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Radioligand Therapy revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:
  • Novartis
  • Advanced Accelerator Applications
  • Mercy Radiology
  • POINT Biopharma Global Inc
  • Fusion Pharma
  • Telix Pharmaceuticals Ltd
  • Lantheus Holdings, Inc
  • Bayer AG
  • Curium Pharma
  • Precirix
1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Radioligand Therapy Market Definition
1.2 Market Segments
  1.2.1 Market by Used Radionuclides
  1.2.2 Market by Application
1.3 Global Radioligand Therapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL RADIOLIGAND THERAPY OVERALL MARKET SIZE

2.1 Global Radioligand Therapy Market Size: 2021 VS 2028
2.2 Global Radioligand Therapy Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Radioligand Therapy Players in Global Market
3.2 Top Global Radioligand Therapy Companies Ranked by Revenue
3.3 Global Radioligand Therapy Revenue by Companies
3.4 Top 3 and Top 5 Radioligand Therapy Companies in Global Market, by Revenue in 2021
3.5 Global Companies Radioligand Therapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Radioligand Therapy Players in Global Market
  3.6.1 List of Global Tier 1 Radioligand Therapy Companies
  3.6.2 List of Global Tier 2 and Tier 3 Radioligand Therapy Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Used Radionuclides - Global Radioligand Therapy Market Size Markets, 2021 & 2028
  4.1.2 Actinium 225 (Ac-225)
  4.1.3 Lutetium 177 (Lu-177)
  4.1.4 Gallium 68 (Ga-68)
  4.1.5 Fluorine 18 (F-18)
  4.1.6 Other Radionuclides
4.2 By Used Radionuclides - Global Radioligand Therapy Revenue & Forecasts
  4.2.1 By Used Radionuclides - Global Radioligand Therapy Revenue, 2017-2022
  4.2.2 By Used Radionuclides - Global Radioligand Therapy Revenue, 2023-2028
  4.2.3 By Used Radionuclides - Global Radioligand Therapy Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Radioligand Therapy Market Size, 2021 & 2028
  5.1.2 Neuroendocrine Neoplasms
  5.1.3 Prostate Cancer
5.2 By Application - Global Radioligand Therapy Revenue & Forecasts
  5.2.1 By Application - Global Radioligand Therapy Revenue, 2017-2022
  5.2.2 By Application - Global Radioligand Therapy Revenue, 2023-2028
  5.2.3 By Application - Global Radioligand Therapy Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Radioligand Therapy Market Size, 2021 & 2028
6.2 By Region - Global Radioligand Therapy Revenue & Forecasts
  6.2.1 By Region - Global Radioligand Therapy Revenue, 2017-2022
  6.2.2 By Region - Global Radioligand Therapy Revenue, 2023-2028
  6.2.3 By Region - Global Radioligand Therapy Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Radioligand Therapy Revenue, 2017-2028
  6.3.2 US Radioligand Therapy Market Size, 2017-2028
  6.3.3 Canada Radioligand Therapy Market Size, 2017-2028
  6.3.4 Mexico Radioligand Therapy Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Radioligand Therapy Revenue, 2017-2028
  6.4.2 Germany Radioligand Therapy Market Size, 2017-2028
  6.4.3 France Radioligand Therapy Market Size, 2017-2028
  6.4.4 U.K. Radioligand Therapy Market Size, 2017-2028
  6.4.5 Italy Radioligand Therapy Market Size, 2017-2028
  6.4.6 Russia Radioligand Therapy Market Size, 2017-2028
  6.4.7 Nordic Countries Radioligand Therapy Market Size, 2017-2028
  6.4.8 Benelux Radioligand Therapy Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Radioligand Therapy Revenue, 2017-2028
  6.5.2 China Radioligand Therapy Market Size, 2017-2028
  6.5.3 Japan Radioligand Therapy Market Size, 2017-2028
  6.5.4 South Korea Radioligand Therapy Market Size, 2017-2028
  6.5.5 Southeast Asia Radioligand Therapy Market Size, 2017-2028
  6.5.6 India Radioligand Therapy Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Radioligand Therapy Revenue, 2017-2028
  6.6.2 Brazil Radioligand Therapy Market Size, 2017-2028
  6.6.3 Argentina Radioligand Therapy Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Radioligand Therapy Revenue, 2017-2028
  6.7.2 Turkey Radioligand Therapy Market Size, 2017-2028
  6.7.3 Israel Radioligand Therapy Market Size, 2017-2028
  6.7.4 Saudi Arabia Radioligand Therapy Market Size, 2017-2028
  6.7.5 UAE Radioligand Therapy Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Novartis
  7.1.1 Novartis Corporate Summary
  7.1.2 Novartis Business Overview
  7.1.3 Novartis Radioligand Therapy Major Product Offerings
  7.1.4 Novartis Radioligand Therapy Revenue in Global Market (2017-2022)
  7.1.5 Novartis Key News
7.2 Advanced Accelerator Applications
  7.2.1 Advanced Accelerator Applications Corporate Summary
  7.2.2 Advanced Accelerator Applications Business Overview
  7.2.3 Advanced Accelerator Applications Radioligand Therapy Major Product Offerings
  7.2.4 Advanced Accelerator Applications Radioligand Therapy Revenue in Global Market (2017-2022)
  7.2.5 Advanced Accelerator Applications Key News
7.3 Mercy Radiology
  7.3.1 Mercy Radiology Corporate Summary
  7.3.2 Mercy Radiology Business Overview
  7.3.3 Mercy Radiology Radioligand Therapy Major Product Offerings
  7.3.4 Mercy Radiology Radioligand Therapy Revenue in Global Market (2017-2022)
  7.3.5 Mercy Radiology Key News
7.4 POINT Biopharma Global Inc
  7.4.1 POINT Biopharma Global Inc Corporate Summary
  7.4.2 POINT Biopharma Global Inc Business Overview
  7.4.3 POINT Biopharma Global Inc Radioligand Therapy Major Product Offerings
  7.4.4 POINT Biopharma Global Inc Radioligand Therapy Revenue in Global Market (2017-2022)
  7.4.5 POINT Biopharma Global Inc Key News
7.5 Fusion Pharma
  7.5.1 Fusion Pharma Corporate Summary
  7.5.2 Fusion Pharma Business Overview
  7.5.3 Fusion Pharma Radioligand Therapy Major Product Offerings
  7.5.4 Fusion Pharma Radioligand Therapy Revenue in Global Market (2017-2022)
  7.5.5 Fusion Pharma Key News
7.6 Telix Pharmaceuticals Ltd
  7.6.1 Telix Pharmaceuticals Ltd Corporate Summary
  7.6.2 Telix Pharmaceuticals Ltd Business Overview
  7.6.3 Telix Pharmaceuticals Ltd Radioligand Therapy Major Product Offerings
  7.6.4 Telix Pharmaceuticals Ltd Radioligand Therapy Revenue in Global Market (2017-2022)
  7.6.5 Telix Pharmaceuticals Ltd Key News
7.7 Lantheus Holdings, Inc
  7.7.1 Lantheus Holdings, Inc Corporate Summary
  7.7.2 Lantheus Holdings, Inc Business Overview
  7.7.3 Lantheus Holdings, Inc Radioligand Therapy Major Product Offerings
  7.7.4 Lantheus Holdings, Inc Radioligand Therapy Revenue in Global Market (2017-2022)
  7.7.5 Lantheus Holdings, Inc Key News
7.8 Bayer AG
  7.8.1 Bayer AG Corporate Summary
  7.8.2 Bayer AG Business Overview
  7.8.3 Bayer AG Radioligand Therapy Major Product Offerings
  7.8.4 Bayer AG Radioligand Therapy Revenue in Global Market (2017-2022)
  7.8.5 Bayer AG Key News
7.9 Curium Pharma
  7.9.1 Curium Pharma Corporate Summary
  7.9.2 Curium Pharma Business Overview
  7.9.3 Curium Pharma Radioligand Therapy Major Product Offerings
  7.9.4 Curium Pharma Radioligand Therapy Revenue in Global Market (2017-2022)
  7.9.5 Curium Pharma Key News
7.10 Precirix
  7.10.1 Precirix Corporate Summary
  7.10.2 Precirix Business Overview
  7.10.3 Precirix Radioligand Therapy Major Product Offerings
  7.10.4 Precirix Radioligand Therapy Revenue in Global Market (2017-2022)
  7.10.5 Precirix Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

LIST OF TABLES

Table 1. Radioligand Therapy Market Opportunities & Trends in Global Market
Table 2. Radioligand Therapy Market Drivers in Global Market
Table 3. Radioligand Therapy Market Restraints in Global Market
Table 4. Key Players of Radioligand Therapy in Global Market
Table 5. Top Radioligand Therapy Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Radioligand Therapy Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Radioligand Therapy Revenue Share by Companies, 2017-2022
Table 8. Global Companies Radioligand Therapy Product Type
Table 9. List of Global Tier 1 Radioligand Therapy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Radioligand Therapy Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Used Radionuclides – Global Radioligand Therapy Revenue, (US$, Mn), 2021 & 2028
Table 12. By Used Radionuclides - Radioligand Therapy Revenue in Global (US$, Mn), 2017-2022
Table 13. By Used Radionuclides - Radioligand Therapy Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Radioligand Therapy Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Radioligand Therapy Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Radioligand Therapy Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Radioligand Therapy Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Radioligand Therapy Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Radioligand Therapy Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Radioligand Therapy Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Radioligand Therapy Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Radioligand Therapy Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Radioligand Therapy Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Radioligand Therapy Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Radioligand Therapy Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Radioligand Therapy Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Radioligand Therapy Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Radioligand Therapy Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Radioligand Therapy Revenue, (US$, Mn), 2023-2028
Table 30. Novartis Corporate Summary
Table 31. Novartis Radioligand Therapy Product Offerings
Table 32. Novartis Radioligand Therapy Revenue (US$, Mn), (2017-2022)
Table 33. Advanced Accelerator Applications Corporate Summary
Table 34. Advanced Accelerator Applications Radioligand Therapy Product Offerings
Table 35. Advanced Accelerator Applications Radioligand Therapy Revenue (US$, Mn), (2017-2022)
Table 36. Mercy Radiology Corporate Summary
Table 37. Mercy Radiology Radioligand Therapy Product Offerings
Table 38. Mercy Radiology Radioligand Therapy Revenue (US$, Mn), (2017-2022)
Table 39. POINT Biopharma Global Inc Corporate Summary
Table 40. POINT Biopharma Global Inc Radioligand Therapy Product Offerings
Table 41. POINT Biopharma Global Inc Radioligand Therapy Revenue (US$, Mn), (2017-2022)
Table 42. Fusion Pharma Corporate Summary
Table 43. Fusion Pharma Radioligand Therapy Product Offerings
Table 44. Fusion Pharma Radioligand Therapy Revenue (US$, Mn), (2017-2022)
Table 45. Telix Pharmaceuticals Ltd Corporate Summary
Table 46. Telix Pharmaceuticals Ltd Radioligand Therapy Product Offerings
Table 47. Telix Pharmaceuticals Ltd Radioligand Therapy Revenue (US$, Mn), (2017-2022)
Table 48. Lantheus Holdings, Inc Corporate Summary
Table 49. Lantheus Holdings, Inc Radioligand Therapy Product Offerings
Table 50. Lantheus Holdings, Inc Radioligand Therapy Revenue (US$, Mn), (2017-2022)
Table 51. Bayer AG Corporate Summary
Table 52. Bayer AG Radioligand Therapy Product Offerings
Table 53. Bayer AG Radioligand Therapy Revenue (US$, Mn), (2017-2022)
Table 54. Curium Pharma Corporate Summary
Table 55. Curium Pharma Radioligand Therapy Product Offerings
Table 56. Curium Pharma Radioligand Therapy Revenue (US$, Mn), (2017-2022)
Table 57. Precirix Corporate Summary
Table 58. Precirix Radioligand Therapy Product Offerings
Table 59. Precirix Radioligand Therapy Revenue (US$, Mn), (2017-2022)

LIST OF FIGURES

Figure 1. Radioligand Therapy Segment by Used Radionuclides in 2021
Figure 2. Radioligand Therapy Segment by Application in 2021
Figure 3. Global Radioligand Therapy Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Radioligand Therapy Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Radioligand Therapy Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Radioligand Therapy Revenue in 2021
Figure 8. By Used Radionuclides - Global Radioligand Therapy Revenue Market Share, 2017-2028
Figure 9. By Application - Global Radioligand Therapy Revenue Market Share, 2017-2028
Figure 10. By Region - Global Radioligand Therapy Revenue Market Share, 2017-2028
Figure 11. By Country - North America Radioligand Therapy Revenue Market Share, 2017-2028
Figure 12. US Radioligand Therapy Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Radioligand Therapy Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Radioligand Therapy Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Radioligand Therapy Revenue Market Share, 2017-2028
Figure 16. Germany Radioligand Therapy Revenue, (US$, Mn), 2017-2028
Figure 17. France Radioligand Therapy Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Radioligand Therapy Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Radioligand Therapy Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Radioligand Therapy Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Radioligand Therapy Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Radioligand Therapy Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Radioligand Therapy Revenue Market Share, 2017-2028
Figure 24. China Radioligand Therapy Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Radioligand Therapy Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Radioligand Therapy Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Radioligand Therapy Revenue, (US$, Mn), 2017-2028
Figure 28. India Radioligand Therapy Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Radioligand Therapy Revenue Market Share, 2017-2028
Figure 30. Brazil Radioligand Therapy Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Radioligand Therapy Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Radioligand Therapy Revenue Market Share, 2017-2028
Figure 33. Turkey Radioligand Therapy Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Radioligand Therapy Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Radioligand Therapy Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Radioligand Therapy Revenue, (US$, Mn), 2017-2028
Figure 37. Novartis Radioligand Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Advanced Accelerator Applications Radioligand Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Mercy Radiology Radioligand Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. POINT Biopharma Global Inc Radioligand Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Fusion Pharma Radioligand Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Telix Pharmaceuticals Ltd Radioligand Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Lantheus Holdings, Inc Radioligand Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Bayer AG Radioligand Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Curium Pharma Radioligand Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Precirix Radioligand Therapy Revenue Year Over Year Growth (US$, Mn) & (2017-2022)



More Publications